We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00295412
First Posted: February 23, 2006
Last Update Posted: February 23, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
AstraZeneca
Information provided by:
Université de Montréal
  Purpose
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our expectation was a 20 % decrease in drug cravings from baseline to end-point.

Condition Intervention Phase
Schizophrenia Substance Use Disorders Drug: quetiapine (drug) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients

Resource links provided by NLM:


Further study details as provided by Université de Montréal:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with as schizophrenia spectrum disorder
  • Patients with a comorbid substance use disorder

Exclusion Criteria:

  • Patients already on quetiapine or clozapine
  • Patients hospitalized or acutely ill
  • Total score lower than 65 on the PANSS
  • Pregnancy
  • Female subjects of childbearing potential without adequate contraception
  • Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
  • Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00295412


Locations
Canada, Quebec
Centre de recherche Fernand-Seguin
Montreal, Quebec, Canada, H1N 3V2
Sponsors and Collaborators
Université de Montréal
AstraZeneca
Investigators
Principal Investigator: Emmanuel Stip, Md, MSc, CSPQ Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Departement of Psychiatry, Faculty of medicine, University of Montreal
  More Information

ClinicalTrials.gov Identifier: NCT00295412     History of Changes
Other Study ID Numbers: 5077-99904
First Submitted: February 21, 2006
First Posted: February 23, 2006
Last Update Posted: February 23, 2006
Last Verified: September 2005

Additional relevant MeSH terms:
Schizophrenia
Substance-Related Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Chemically-Induced Disorders
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs